PharmaGraphX

Log in Get Started

Atezolizumab

Tecentriq, Tecentriq Hybreza

Monoclonal antibody

Standard

Half-life

27 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Clinical alerts

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Monoclonal antibody blocking PD-L1, preventing interaction with PD-1 and B7.1

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Limited Stage Lung Small Cell Carcinoma
·Stage I Lung Cancer AJCC v8
·Stage II Lung Cancer AJCC v8
·Stage III Lung Cancer AJCC v8
·Lung Non-Small Cell Carcinoma

Interactions

No curated interaction pairs are recorded for Atezolizumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Fatigue
Decreased appetite
Nausea
Immune-mediated adverse events

Pharmacokinetics

Half-life: 27 days
Protein binding: N/A

Pregnancy & lactation

Not recorded for Atezolizumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement